YIH
CTKB icon

Y-Intercept (HK)’s Cytek Biosciences CTKB Stock Holding History

Y-Intercept (HK)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
+193,128
New +$824K 0.02% 1108
2023
Q4 		– Sell
-19,234
Closed -$106K – 1295
2023
Q3 		$106K Buy
+19,234
New +$154K 0.01% 968

Other funds holding CTKB

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $169M AUM 22.99% 1-Year Est. Return

Y-Intercept (HK)'s CTKB Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 193,128 shares worth $856K. The stake represents 0.02% of the portfolio and ranks #1108 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CTKB as recently as Q3 2023.

Y-Intercept (HK) first reported a position in CTKB in Q3 2023 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Y-Intercept (HK) held 193,128 shares of Cytek Biosciences worth $856K as of Q2 2026.
  • Cytek Biosciences was a new Y-Intercept (HK) position in Q2 2026.
  • Cytek Biosciences made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1108 holding.
  • Y-Intercept (HK) first reported a position in Cytek Biosciences in Q3 2023 and has held it in 2 quarters since.
  • 8 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.